Chronic hypertension classification: Difference between revisions
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
Line 19: | Line 19: | ||
! colspan="4" align="center" style="background:#DCDCDC;" |2014 Hypertension Guideline | ! colspan="4" align="center" style="background:#DCDCDC;" |2014 Hypertension Guideline | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Methodology | |align="left" style="background:#DCDCDC;"|'''Methodology''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" | Nonsystematic literature review by expert committee including a | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" | Nonsystematic literature review by expert committee including a | ||
range of study designs | range of study designs | ||
Line 35: | Line 35: | ||
panel according to a standardized protocol | panel according to a standardized protocol | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Definitions | |align="left" style="background:#DCDCDC;"|'''Definitions''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Defined hypertension and prehypertension | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Defined hypertension and prehypertension | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Definitions of hypertension and prehypertension not addressed, | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Definitions of hypertension and prehypertension not addressed, | ||
but thresholds for pharmacologic treatment were defined | but thresholds for pharmacologic treatment were defined | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Treatment | |align="left" style="background:#DCDCDC;"|'''Treatment goals''' | ||
goals | |||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" | Separate treatment goals defined for “uncomplicated” hypertension | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" | Separate treatment goals defined for “uncomplicated” hypertension | ||
and for subsets with various comorbid conditions | and for subsets with various comorbid conditions | ||
Line 51: | Line 50: | ||
subpopulation | subpopulation | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Lifestyle | |align="left" style="background:#DCDCDC;"|'''Lifestyle | ||
recommendations | recommendations''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Recommended lifestyle modifications based on literature review and | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Recommended lifestyle modifications based on literature review and | ||
expert opinion | expert opinion | ||
Line 58: | Line 57: | ||
Recommendations of the Lifestyle Work Group | Recommendations of the Lifestyle Work Group | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Drug therapy | |align="left" style="background:#DCDCDC;"|'''Drug therapy''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Recommended 5 classes to be considered as initial therapy but recommended | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Recommended 5 classes to be considered as initial therapy but recommended | ||
thiazide-type diuretics as initial therapy for most patients | thiazide-type diuretics as initial therapy for most patients | ||
Line 82: | Line 81: | ||
Panel created a table of drugs and doses used in the outcome trials | Panel created a table of drugs and doses used in the outcome trials | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Scope of topics | |align="left" style="background:#DCDCDC;"|'''Scope of topics''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Addressed multiple issues (blood pressure measurement methods, | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Addressed multiple issues (blood pressure measurement methods, | ||
patient evaluation components, secondary hypertension, adherence | patient evaluation components, secondary hypertension, adherence | ||
Line 92: | Line 91: | ||
those judged by the panel to be of highest priority. | those judged by the panel to be of highest priority. | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Pre-publication review | |align="left" style="background:#DCDCDC;"|'''Pre-publication review''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Reviewed by the National High Blood Pressure Education Program | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Reviewed by the National High Blood Pressure Education Program | ||
Coordinating Committee, a coalition of 39 major professional, public, | Coordinating Committee, a coalition of 39 major professional, public, |
Revision as of 15:14, 17 May 2017
Chronic Hypertension Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Chronic hypertension classification On the Web |
Directions to Hospitals Treating Chronic hypertension classification |
Risk calculators and risk factors for Chronic hypertension classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor-In-Chief: Yazan Daaboul, Serge Korjian
Overview
In 2004, the Seventh Report of the Joint National Committee (JNC 7) classified blood pressure values into 4 categories: normal, prehypertension, stage I hypertension, and stage II hypertension.[1] In 2007, the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) classified blood pressure into 7 categories.[2] This classification remained unchanged in the 2013 ESH/ESC classification.[3] The ESH/ESC classification excludes JNC 7’s pre-hypertension category, but includes 3 different grades of hypertension in contrast to JNC 7’s two-stage classification of hypertension.
Classification
2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults (JNC8) -- DO NOT EDIT
|
Abbreviations:
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; JNC, Joint National Committee;
RCT, randomized controlled trial.
Adopted from 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).[4]
JNC 7 Classification of Blood Pressure
According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[5] blood pressure values were classified as follows:
Blood Pressure Classification | Systolic (mm Hg) | Diastolic (mm Hg) | |
Normal | < 120 | and | < 80 |
Pre-Hypertension | 120-139 | or | 80-89 |
Stage 1 Hypertension | 140-159 | or | 90-99 |
Stage 2 Hypertension | >160 | or | >100 |
ESH/ESC Classification of Blood Pressure
In Europe, a different classification of blood pressure was introduced in 2007 by The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). According to the 2013 Guidelines for the Management of Arterial Hypertension, blood pressure values were classified as follows: [2]
Blood Pressure Classification | Systolic (mm Hg) | Diastolic (mm Hg) | |
Optimal | < 120 | and | < 80 |
Normal | 120-129 | and/or | 80-84 |
High Normal | 130-139 | and/or | 85-89 |
Grade 1 Hypertension | 140-159 | and/or | 90-99 |
Grade 2 Hypertension | 160-179 | and/or | 100-109 |
Grade 3 Hypertension | ≥ 180 | and/or | ≥110 |
Isolated Systolic Hypertension | ≥140 | and | <90 |
References
- ↑ Cuddy ML (2005). "Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1)". J Pract Nurs. 55 (4): 17–21, quiz 22-3. PMID 16512265.
- ↑ 2.0 2.1 Bonny A, Lacombe F, Yitemben M, Discazeaux B, Donetti J, Fahri P; et al. (2008). "The 2007 ESH/ESC guidelines for the management of arterial hypertension". J Hypertens. 26 (4): 825, author reply 825-6. doi:10.1097/HJH.0b013e3282f857e7. PMID 18327095.
- ↑ Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M; et al. (2013). "2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)". J Hypertens. 31 (7): 1281–357. doi:10.1097/01.hjh.0000431740.32696.cc. PMID 23817082.
- ↑ James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J; et al. (2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)". JAMA. 311 (5): 507–20. doi:10.1001/jama.2013.284427. PMID 24352797.
- ↑ Chobanian AV; et al. (2003). "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report". JAMA. 289: 2560–72. PMID 12748199.